The EMA recommends continuing to give the second dose of AstraZeneca between 4 and 12 weeks after the first.



The European Medicines Agency recommends continuing to give the second dose of AstraZeneca between 4 and 12 weeks after the first. And he considers that it should be administered in all age groups. This was transmitted this Friday through a statement. Nzoël Wathion, EMA Deputy Executive Director, said: “Overall, the data shows that the benefits of vaccination increase with age and with high levels of infection in the community.”

“Vaxzevria (formerly COVID-19 Vaccine AstraZeneca) is authorized in the EU to prevent COVID-19, which can cause serious illness and death. The disease can also have long-term consequences in people of all ages, including people otherwise healthy, “states the EMA statement:” The benefits of Vaxzevria outweigh its risks in adults of all ages; however, very rare cases of blood clots with low platelets have occurred after vaccination. ”

In any case, the EMA states: “Vaxzevria is effective in preventing hospitalizations, intensive care unit (ICU) admissions and deaths from COVID-19. The most common side effects are usually mild or moderate and improve within a few days. The most serious side effects are very rare cases of unusual blood clots with low platelets, which are estimated to occur in 1 in 100,000 vaccinated people. ”

The EMA has analyzed “the benefits of the vaccine and the risk of unusual blood clots with low platelets in different age groups in the context of monthly infection rates: low (55 per 100,000 people), medium (401 per 100,000 people) and high (886 per 100,000 people). people) “.

“The analysis examined the prevention of hospitalizations, ICU admissions and deaths from COVID-19, based on different assumptions of the efficacy of the vaccine to contextualize the occurrence of these unusual blood clots,” says the EMA: “It showed that the benefits of vaccination increases with increasing age and infection rates. There was insufficient data from across the EU to provide additional context on the benefits and risks with respect to gender. ”

The risk-benefit balance analysis of the vaccine remains positive for adults of all age groups, insists the EMA: “Like all vaccines, Vaxzevria is approved because its benefits outweigh the risks for a person potentially exposed to the agent that causes disease. ”

The Agency further “recommends continuing to administer a second dose of Vaxzevria between 4 and 12 weeks after administering the first according to the product information.”


.



Source link